key: cord-0870748-hyk0irco
authors: Hekimoglu, Baris; Beyoglu, Muhammet Ali
title: Early outcomes of lung resections in non-small cell lung cancer after COVID-19 pneumonia
date: 2022-05-02
journal: Asian J Surg
DOI: 10.1016/j.asjsur.2022.04.080
sha: 4abe170b8e1e35d37af2efc799d17f118b871ecd
doc_id: 870748
cord_uid: hyk0irco

OBJECTIVE: There is limited literature on patients with a history of COVID-19 pneumonia who underwent anatomical lung resection for non-small cell lung cancer (NSCLC). This study was aimed to share the early postoperative outcomes in patients who underwent lung resection after COVID-19 pneumonia. MATERIALS AND METHODS: We retrospectively evaluated 30 patients who underwent lobectomy with thoracotomy and systematic mediastinal lymph node dissection due to NSCLC in a single center between November 2018 and September 2021. The patients were divided into two groups regarding COVID-19 pneumonia history; the COVID-19 group consisted of 14 patients (46.7%) and the non-COVID-19 group 16 (53.3%) patients. The patients’ age, gender, comorbidity, Charlson Comorbidity Index (CCI) score, forced expiratory volume in 1 s (FEV1) value, tumor type and size, resection type, postoperative air leak duration, total drainage volume, drain removal time, postoperative complications, and length of stay (LOS) were recorded. RESULTS: 9 (30%) patients were female, and 21 (70%) were male. The mean age was 62.1 ± 8.91 years. Our comparison of postoperative air leak duration, total drainage volume, time to drain removal, postoperative complications, and LOS between the COVID-19 and non-COVID-19 groups revealed no statistically significant difference. CONCLUSION: Anatomical lung resection can be performed safely in NSCLC patients with a history of COVID-19 pneumonia without significant difference in early postoperative morbidity and mortality.

The coronavirus disease 2019 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has entailed a global crisis in the health system since the first half of 2020. 1, 2 The pandemic not only impacted daily life dramatically but also led to the death of millions of people. 3 As of October 2021, approximately 239 million confirmed cases of COVID-19 and 4.87 million related deaths had been reported worldwide. According to World Health Organisation (WHO) data, about 234.1 million people have recovered from the disease so far. 1 The SARS-CoV-2 can result in a broad spectrum of outcomes in its primary target, the lung, ranging from complete recovery to widespread sequelae. 4 The early phase of SARS-CoV-2 infection generally manifests with diffuse pulmonary infiltrates, mucosal damage as a result of viremia in the bronchi, development of alveolitis and vasculitis, and distal parenchymal injury, whereas the later phase involves injury due to the weakening of mucosal and distal parenchymal connective tissue as a result of long-term corticosteroids use and pulmonary fibrosis. 5 A history of COVID-19 pneumonia is increasingly common in patients scheduled for elective thoracic surgery. Early diagnosis and treatment are crucial in managing conditions that necessitate surgery, such as lung cancer, chest wall, and mediastinal diseases. Besides, it is clinically vital to provide the appropriate medical environment for patients who require thoracic surgery during the COVID-19 pandemic. 6, 7 There is limited published literature on the rates of complication, morbidity, and mortality rates in patients with a history of COVID-19 pneumonia who underwent anatomical lung resection for NSCLC. In this study, we share the early postoperative outcomes in patients with these features operated in our center and compare them with anatomical lung resection outcomes before the pandemic.

J o u r n a l P r e -p r o o f

Our study has a retrospective, descriptive and cross-sectional design and was approved by the local ethics committee (Approval No:2021/206). The study population consisted of 30 patients who underwent lobectomy with thoracotomy and systematic mediastinal lymph node dissection due to NSCLC in our center between November 2018 and September 2021. Patients with less than 4% desaturations during the stair-climbing test were considered suitable for lung resection. Informed consent was obtained from all patients participating in the study before the operation. Possible risks and uncertainties related to COVID-19 were also mentioned, and informed consent was obtained from the patients in COVID-19 group. Our surgical team omitted lobectomy for NSCLC in patients with distant metastases, mediastinal lymph node positivity, and features unfavorable for achieving R0 surgical margins with lobectomy. We performed all surgeries under general anesthesia with a double-lumen endotracheal tube followed by a posterolateral thoracotomy. The team used a thoracoabdominal stapler (4.8 mm height) for bronchial divisions and a linear stapler (4.8 mm height) for pulmonary fissure divisions.

Patients with a history of COVID-19 underwent surgery at least six weeks after the disease, following extensive preoperative preparation. From March 11, 2020, when the first case of SARS-CoV-2 infection was officially reported, all patients submitted two combined oropharyngeal-nasal swabs taken 48 hours apart for SARS-CoV-2 RT-PCR testing before J o u r n a l P r e -p r o o f surgery. Only patients with negative results qualify for surgery. We performed the surgeries with minimal staff, and the surgical team wore full personal protective equipment (PPE).

IBM SPSS for Windows Version 22.0 (SPSS Inc., Chicago, IL, USA) was used for statistical analysis. Descriptive data were presented as frequency and percentage for categorical variables and mean and standard deviation (median+range) for quantitative variables. The conformity of data to normal distribution was checked with the Shapiro-Wilk test. In subgroups, univariate analyzes were performed using the chi-squared test and Mann-Whitney U-test. A p-value <0.5 was considered statistically significant.

A total of 30 patients underwent lobectomy and systematic mediastinal lymph node dissection for NSCLC. 9 (30%) patients were female, and 21 (70%) were male. The mean age was 62.1±8.91 years. The COVID-19 group consisted of 14 patients. 4 of them were female, and 10 were male. The mean age of the group was 60.7. Lung cancer was detected on COVID-19 imaging in 9 (64.2%) of the patients, while it was discovered in 5 (35.8%) of the patients during subsequent clinical evaluations. There were 16 patients in the non-COVID-19 group. 5 of them were female, and 11 were male. In the whole cohort, 11 (36.6%) patients had essential hypertension, 10 (30%) diabetes mellitus, 5 (16.7%) chronic obstructive pulmonary disease (COPD), 2 (6.6%) asthma, 2 (6.6%) heart valve disease, 1 (3.3%) atrial fibrillation and 1 (3.3%) chronic renal failure. 5 patients (16.7%) had no comorbidities. The Charlson Comorbidity indexes and pulmonary function test results by groups are presented in Table 1 . Furthermore, the mean total drainage volume was 725 ± 619.4 ml in the COVID-19 group and 893.7 ± 565 ml in the non-COVID group (p=0.355). Moreover, the mean time to drain removal was 6.36 ± 2.46 days in the COVID-19 group and 4.69 ± 1.49 days in the non-COVID-19 group. The difference was not significant between groups (p=0.052) ( Table 2) . In the non-COVID-19 group, 2 (12.5%) patients had wound site infections (Table 3) .

There were also pulmonary, cardiac, and cerebrovascular complications in our cohort. staged as IB, one patient (3.3%) was staged as IIA, two patients (6.6%) were staged as IIB, and four patients (3.3%) were staged as IIIA. Nine patients (64.3%) were staged as IA, two (14.3%) as IB, one (7.1%) as IIB, and two (14.3%) as IIIA in the COVID-19 group. Table 4 shows the pathological stages of patients in the COVID-19 group according to the time of the lung cancer diagnosis.

The present study is one of the few in the literature to investigate early postoperative outcomes in patients with a history of COVID-19 pneumonia who underwent anatomical lung resection for NSCLC. Postoperative air leak duration, total drainage volume, time to drain J o u r n a l P r e -p r o o f removal, postoperative complications, and LOS between the COVID-19 and non-COVID-19 groups revealed no statistically significant difference.

for increased length of stay, morbidity, and mortality. 8 Studies report the rate of postoperative persistent air leakage between 2.38-13.3% in patients who underwent lobectomy for NSCLC. [12] [13] [14] [15] In the present study, persistent air leakage was observed in two (14.2%) patients in the COVID-19 group, which was in line with the literature. days. [14] [15] [16] [17] In the present study, the mean LOS was 7.64 ± 2.49 days in the COVID-19 group 18 The complication rates in the present study also attest to the viability of anatomical lung resection in patients with similar characteristics.

Three of the patients in the COVID-19 group underwent surgery in the pathologically advanced stage. The lung mass could not be diagnosed on COVID-19 imaging in two of these patients. Despite the limited number of patients in our study, it is noteworthy that the pathological stages of patients with a history of COVID-19 pneumonia diagnosed with lung cancer in the later period were more advanced. Delaying surgery for stage 1 NSCLC by 8 weeks was linked to pathological upstaging of the tumor, higher 30-day mortality, and shorter median survival, according to a large cohort study of 40,000 patients. 19 Although the results of our study report that lung resection can be performed safely in patients with COVID-19 pneumonia, clinical, radiological, or laboratory evaluation methods are needed to determine the optimum time for early surgery in these patients.

Since the long-term effects of COVID-19 infection are still unclear, our investigation of early postoperative outcomes has been based on a relatively small cohort. As time proceeds, there will be many more cases of lung resection in patients with a history of COVID-19 infection, allowing future studies with larger study populations.

COVID-19 infection primarily affects the lungs. However, the present study has shown that lung resection can be performed safely in NSCLC patients with a history of COVID-19 pneumonia without significant difference in early postoperative morbidity and mortality. Nevertheless, randomized controlled trials with a higher number of patients are necessary to draw firmer conclusions. J o u r n a l P r e -p r o o f 

It was unanimously decided by the participants of the meeting that the research titled "Lung Resections in Non-Small Cell Lung Cancer after COVID-19 Pneumonia" by the responsible coordinator researcher Dr. Baris HEKIMOGLU was approved as a result of the evaluation of the application numbered CREC 223.

Coronavirus Disease (COVID-19) dashboard

Clinical Characteristics of Coronavirus Disease 2019 in China

Estimates of the severity of coronavirus disease 2019: a model-based analysis

Pulmonary Pathology of COVID-19 Following 8 Weeks to 4 Months of Severe Disease: A Report of Three Cases, Including One With Bilateral Lung Transplantation

Pulmonary pathology and COVID-19: lessons from autopsy. The experience of European Pulmonary Pathologists

General thoracic surgery services across Asia during the 2020 COVID-19 pandemic

Challenges in lung cancer therapy during the COVID-19 pandemic

Maintaining safe lung cancer surgery during the COVID-19 pandemic in a global city

1-year radiological, functional and quality-of-life outcomes in patients with SARS-CoV-2 pneumonia -A prospective observational study

Management of Lung Cancer During the COVID-19 Pandemic

Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection

Comparison of pulmonary segmentectomy and lobectomy: Safety results of a randomized trial

Thoracoscopic Surgery Versus Thoracotomy for Lung Cancer: Short-Term Outcomes of a Randomized Trial

Comparison of the Video-assisted Thoracoscopic Lobectomy versus Open Thoracotomy for Primary Non-Small Cell Lung Cancer: Single Cohort Study with 269

Relative incremental costs of complications of lobectomy for stage I non-small cell lung cancer

Surgery for early-stage non-small cell lung cancer: a systematic review of the video-assisted thoracoscopic surgery versus thoracotomy approaches to lobectomy

Video-assisted thoracoscopic versus open thoracotomy lobectomy: a Swedish nationwide cohort study

Pulmonary Lobectomy After COVID-19

Effects of delayed surgical resection on short-term and long-term outcomes in clinical stage I